Hanna Leinonen

FinVector (Finland) — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

19h-index2.9kcitations38works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(13), Genomics, phytochemicals, and oxidative stress(12), Viral Infectious Diseases and Gene Expression in Insects(7), RNA Interference and Gene Delivery(6), Glutathione Transferases and Polymorphisms(5)

Publications37 total

Industrialisation of Adenoviral Vector Production in Fixed Bed Bioreactor: A control strategy for a Monoseptic process
2025Open Access
Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing
Cytotherapy·2024· 2 citedOpen Access
Supplementary Figure 1 from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Data from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Supplementary Figure Legend from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Data from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Supplementary Figure Legend from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Supplementary Figure 1 from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy
Frontiers in Medicine·2023Open Access
Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy
Frontiers in Medicine·2022· 14 citedOpen Access
Thinking big: the need for innovation in the production of lentivirus-based cell and gene therapies
Cell and Gene Therapy Insights·2022Open Access
Commercial-scale lentiviral vector manufacturing: is the myth busted?
Cell and Gene Therapy Insights·2022· 3 cited
Thinking big: the need for innovation in the production of lentivirus-based cell and gene therapies
Cell and Gene Therapy Insights·2021Open Access
Development of Large-Scale Downstream Processing for Lentiviral Vectors
Molecular Therapy — Methods & Clinical Development·2020· 66 citedOpen Access
Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production
Human Gene Therapy·2020· 26 citedOpen Access
Detection of lentiviral suicide gene therapy in C6 rat glioma using hyperpolarised [1‐<sup>13</sup>C]pyruvate
NMR in Biomedicine·2020· 6 citedOpen Access
Preclinical Proof-of-Concept, Analytical Development, and Commercial Scale Production of Lentiviral Vector in Adherent Cells
Molecular Therapy — Methods & Clinical Development·2019· 27 citedOpen Access
Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma
Oncogene·2019· 87 citedOpen Access
Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor
Gene Therapy·2017· 86 citedOpen Access
Pro-nociceptive migraine mediator CGRP provides neuroprotection of sensory, cortical and cerebellar neurons via multi-kinase signaling
Cephalalgia·2016· 32 cited
page 1 of 2Next →

Frequent Co-authors

Seppo Ylä‐Herttuala(23), Anna–Liisa Levonen(22), Emilia Kansanen(16), Hanna P. Lesch(15), Suvi Linna-Kuosmanen(12), Heidi M. Laitinen(8), Ann‐Marie Määttä(8), Haritha Samaranayake(8), Eevi M. Lipponen(7), Anna‐Kaisa Ruotsalainen(7), Jere T. Pikkarainen(7), Jari P. Lappalainen(7), Minna U. Kaikkonen(7), Sergei Häyrynen(5), Henna-Kaisa Jyrkkänen(5), Anniina J. Valkama(5), Petri Pölönen(4), Vesa Turkki(4), Igor Oruetxebarria(4), Piia Käyhty(4)